Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.455 AUD | +4.60% | -1.09% | +31.88% |
May. 17 | Capital One Initiates Immutep at Overweight Rating With $10 Price Target | MT |
May. 15 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.88% | 345M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial